Axol Bioscience - August Newsletter
In amongst the summer sun, the Axol team has been hard at work building better model of human diseases with our market leading iPSC-derived cells. We've also been busy working locally with our distributor partners, getting ready for the busy conference season, and supporting our customers to get the best from their iPSC-derived models. We have also taken some time to answer frequently asked questions about neurological immune cells, and summarize recent publications where our products are being used for high quality translational research.
Key August highlights included :
Working with our network of distribution partners
Our trusted distributors are aligned with our company values and are equally committed to the ultimate mission: unlocking iPSC technology for the global biopharma market to drive better research models and ultimately better therapies.
As our distributors represent our products in their local areas, we ensure they are fully trained to support Axol iPSC-derived products.
This month, it was the turn of our new UK and Ireland distributor Cambridge Bioscience to receive on-site product training for their sales and marketing team.
We're looking forward to traveling with their sales team, spreading the word about better human disease models.
Our distribution partners are:
Click here to see the full list of Axol Bioscience Distributors
Online Poll - Which Neuroscience conferences will you attend?
Our LinkedIn poll told us that the Society for Neuroscience meeting in Chicago is the neuroscience conference people are most likely to attend this year.
Axol Bioscience will also be attending, meeting up with existing partners and initiating new relationships with future collaborators and clients.
We're looking forward to hearing about new developments in neuroscience, and hearing about the challenges of developing models for neuroscience research and drug discovery.
As leading suppliers of high-quality human iPSCs, we’re helping to build more relevant?in vitro?models for neurodegenerative disease research and drug screening and we offer a catalog of high-quality neurons and neuroinflammatory cells:?
We look forward to seeing you there, but if you want to get in touch beforehand to discuss how we can help with your research, don't hesitate to drop us a line at [email protected]
领英推荐
New Publication Featuring axoCells human iPSC-derived atrial cardiomyocytes
August saw the publication of a new high-quality publication that our team have been involved in, "Activation of IP3R in atrial cardiomyocytes leads to generation of cytosolic cAMP" (Akerman et al, 2024)
As part of the study, axoCells human iPSC-derived atrial cardiomyocytes were cultured on a microelectrode array (MEA) and Field Action Potentials (FAP) and contractility were recorded while the α-AR agonist, PE was added to the culture at increasing concentrations.
The researchers found that indirect activation of the IP3 pathway in atrial myocytes using an alpha adrenergic receptor (α-AR) agonist phenylephrine (PE), and direct activation using IP3-AM, leads to an increase in cAMP and that these changes can be pharmacologically inhibited using IP3R inhibitors.
axoCells?atrial cardiomyocytes represent a highly validated, physiologically relevant model and have been extensively characterized structurally, functionally and morphologically. Protein and gene expression, beat rate and action potential parameters, along with functionality of the core cardiac and atrial-specific ion channels have been reported.
The full paper can be found here, 10.1152/ajpheart.00152.2024
Publications Round Up
This month we're also highlighting some of the recently released papers that feature axoCells. Here are some that caught our eye:
It's great to see Axol's products being used in high quality translational research.
Frequently Asked Questions on Neurological Immune Cells
Jessica Tilman PhD., took time out from her busy role as Scientific Group Leader at Axol, to answer frequently asked questions about neurological immune cells. Jess is deeply involved in both microglia based product development and the delivery of service projects. She works in the cellular science group, and regularly participates in custom service projects, testing compounds on healthy and disease lines for disease specific phenotypes.
Read the full interview here: Frequently asked questions for neurological immune cells ( axolbio.com )
Upcoming Conferences
Our events planning team have been busy this month. Come and see us if you're attending one of the following conferences in the autumn:
If you are interested in using human iPSC-derived cells in your work, contact us at [email protected] .
#iPSCs #cardiomyoctes #DrugDiscovery #StemCells #biopharma #MicroelectrodeArray #Neuroscience